AXSM 250516 130.00C(AXSM250516C130000) Stock Price Today

US OptionsDetailed Quotes

AXSM250516C130000

Watchlist

0.50
+0.25+100.00%

15min DelayClose Apr 28 15:54 ET

0.50High0.50Low

Intraday

5D
Daily

News

Express News | Axsome Therapeutics Inc : UBS Cuts Target Price to $143 From $149
ReutersApr 28 10:37 ET
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Yahoo FinanceApr 28 10:00 ET
Investors in Axsome Therapeutics (NASDAQ:AXSM) Have Seen Strong Returns of 235% Over the Past Three Years
Simply Wall StApr 27 08:13 ET
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $190
Moomoo NewsApr 22 02:39 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Axsome Therapeutics (AXSM) and Greenwich LifeSciences (GLSI)
TipRanksApr 21 06:21 ET · Ratings
Positive Outlook on Axsome Therapeutics' AXS-12 for Narcolepsy Treatment Amid Promising Phase III Results
TipRanksApr 14 06:36 ET

Comments

Teddy123

Apr 1 19:05

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

$Axsome Therapeutics (AXSM.US)$
Axsome's MDD Drug Trial Reveals Unexpected Win in Sleepiness Subgroup

Teddy123

Mar 5 21:04

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

$Axsome Therapeutics (AXSM.US)$
Axsome Wins 16+ Years of Market Exclusivity for Sunosi in Patent Settlement

Teddy123

Mar 3 20:09

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

$Axsome Therapeutics (AXSM.US)$
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

Teddy123

Feb 24 20:18

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

$Axsome Therapeutics (AXSM.US)$
Can This New Migraine Drug Replace CGRP Inhibitors? Trial Shows 48x Success Rate

Teddy123

Feb 18 20:17

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

$Axsome Therapeutics (AXSM.US)$
Axsome Shatters Expectations: Record 89% Growth for Depression Drug Auvelity, Pipeline Milestones Accelerate